Recombinant LipL32 and LigA from Leptospira are unable to stimulate protective immunity against leptospirosis in the hamster model

Abstract The major antigenic component of pathogenic Leptospira spp. is lipopolysaccharide (LPS). However, due to the specificity of the immune response generated towards LPS and the diversity in leptospiral LPS carbohydrate structure, current commercial vaccines stimulate protection only against ho...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 29; no. 18; pp. 3413 - 3418
Main Authors Deveson Lucas, Deanna S, Cullen, Paul A, Lo, Miranda, Srikram, Amporn, Sermswan, Rasana W, Adler, Ben
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 18.04.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract The major antigenic component of pathogenic Leptospira spp. is lipopolysaccharide (LPS). However, due to the specificity of the immune response generated towards LPS and the diversity in leptospiral LPS carbohydrate structure, current commercial vaccines stimulate protection only against homologous or closely related serovars. Vaccines that confer heterologous protection would enhance protection in vaccinated animals and reduce transmission to humans. Several studies have investigated the potential of various leptospiral outer membrane proteins to stimulate protective immunity against pathogenic Leptospira species. These include the surface-exposed lipoproteins LipL32 and LigA. However, consistent protection from infection has proved difficult to reproduce. In this study we assessed the protective capacity of recombinant LipL32, the six carboxy-terminal unique Ig-like repeat domains of LigA (LigANI) and a LipL32–LigANI fusion protein in hamsters against infection with Leptospira interrogans serovar Manilae. Despite all of the proteins eliciting antibody responses, none of the hamsters was protected against infection.
Bibliography:http://dx.doi.org/10.1016/j.vaccine.2011.02.084
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.02.084